Dyadic International Inc DYAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
iAccess Alpha Virtual Best Ideas Fall Investment Conference Begins Today with Updated Presentation Schedule
iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
Q3 Virtual Investor Summit Presentations Now Available On Demand
Investor Summit | MicroCap Opportunities to Watch - August 26
Dyadic International, Inc. Secures $2.9 Million Through Registered Direct Offering and Concurrent Private Placement
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Trading Information
- Previous Close Price
- $0.37
- Day Range
- $0.33–0.37
- 52-Week Range
- $0.33–1.60
- Bid/Ask
- $0.34 / $0.36
- Shares Outstanding
- 40.06M
- Market Cap
- $13.63M
- Volume/Avg
- 196 / 157,152
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.13
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.dyadic.com
Valuation
Metric | DYAI |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 9.13 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | DYAI |
|---|---|
Quick Ratio | 1.14 |
Current Ratio | 1.65 |
Interest Coverage | −16.59 |
Quick Ratio
DYAI
Profitability
Metric | DYAI |
|---|---|
Return on Assets (Normalized) | −78.80% |
Return on Equity (Normalized) | −6,747.32% |
Return on Invested Capital (Normalized) | −130.75% |
Return on Assets
DYAI
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|m<!PQ! | LOCK|>fF<J | $138B | |||
| Moderna Inc MRNA | LOCK|B&<$##@ | LOCK|JjL | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|rpLwF< | LOCK|!%!& | $93B | |||
| argenx SE ADR ARGX | LOCK|V@j#w! | LOCK|RF | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%#&Vhx | LOCK|Pm | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!!$T%zN | LOCK|>bN&Z | $30B | |||
| Incyte Corp INCY | LOCK|h%w!!b | LOCK|hs | $24B | |||
| BioNTech SE ADR BNTX | LOCK|B@&@ZV | LOCK|@g% | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!l#<sS | LOCK|@R%z? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|t&&&$$ | LOCK|%F | $15B |
United States